GSK To Tout Positive Advair Study As Defense Against AstraZeneca Symbicort
This article was originally published in The Pink Sheet Daily
Executive Summary
New head-to-head study will provide "the ammunition to continue to…build the Advair franchise" in the U.S., GSK's Stout says. Since AstraZeneca's Symbicort is not approved in the U.S., the most immediate impact of the CONCEPT trial may be to help regain market share in the international market.